Research Study

A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma
Principal Investigator 
Mark FitzGerald

Overview

Body Locations and Systems 
Asthma
ClinicalTrials.gov# 
NCT02555683
Status 
Recruiting
Study Start/End 
Apr 1, 2016 to Jan 1, 2019
Locations 
Diamond Health Care Centre
Name/Title 
Shelley Ambercromby, Research Coordinator
Phone 
604-875-4111 ext.62500
Purpose of Study 

This study aims to determine the efficacy and safety of QAW039 (Dose 1 and Dose 2), compared with placebo, when added to GINA steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2015) in each of the groups (patients with severe asthma and high eosinophil counts and all patients with severe asthma).

Recruitment poster

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.